Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (51-60 of 357) with videos related to

Pageof 36
Sort By:
Current Opinion in Oncology|January 8, 2016
Novel cytotoxic drugs in advanced nonsmall cell lung cancerCesare Gridelli, Paola Claudia Sacco
Chest|August 16, 2005
Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidenceCesare Gridelli, Frances A Shepherd
Current Opinion in Oncology|March 7, 2002
Individualized chemotherapy for elderly patients with nonsmall cell lung cancerCesare Gridelli, Paolo Maione, Emiddio Barletta
Expert Opinion on Drug Safety|November 1, 2005
Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patientsAntonio Rossi, Paolo Maione, Cesare Gridelli
Critical Reviews in Oncology/Hematology|June 30, 2006
Cetuximab in advanced non-small cell lung cancerAntonio Rossi, Paolo Maione, Cesare Gridelli
Current Opinion in Oncology|February 24, 2005
Treatment of non-small cell lung cancer and targeted therapies: where are we?Cesare Gridelli, Antonio Rossi, Paolo Maione
Expert Opinion on Emerging Drugs|September 26, 2018
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitorsAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapyCesare Gridelli, Antonio Rossi, Paolo Maione
Oncology (Williston Park, N.Y.)|May 11, 2006
Treatment of stage I-III non-small-cell lung cancer in the elderlyCesare Gridelli, Paolo Maione, Antonio Rossi
The Oncologist|February 29, 2008
The potential role of mTOR inhibitors in non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Pageof 36

Showing results (51-60 of 357) with videos related to

Sort By:
Pageof 36
Current Opinion in Oncology|January 8, 2016
Novel cytotoxic drugs in advanced nonsmall cell lung cancerCesare Gridelli, Paola Claudia Sacco
Chest|August 16, 2005
Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidenceCesare Gridelli, Frances A Shepherd
Current Opinion in Oncology|March 7, 2002
Individualized chemotherapy for elderly patients with nonsmall cell lung cancerCesare Gridelli, Paolo Maione, Emiddio Barletta
Expert Opinion on Drug Safety|November 1, 2005
Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patientsAntonio Rossi, Paolo Maione, Cesare Gridelli
Critical Reviews in Oncology/Hematology|June 30, 2006
Cetuximab in advanced non-small cell lung cancerAntonio Rossi, Paolo Maione, Cesare Gridelli
Current Opinion in Oncology|February 24, 2005
Treatment of non-small cell lung cancer and targeted therapies: where are we?Cesare Gridelli, Antonio Rossi, Paolo Maione
Expert Opinion on Emerging Drugs|September 26, 2018
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitorsAlessia Spagnuolo, Paolo Maione, Cesare Gridelli
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapyCesare Gridelli, Antonio Rossi, Paolo Maione
Oncology (Williston Park, N.Y.)|May 11, 2006
Treatment of stage I-III non-small-cell lung cancer in the elderlyCesare Gridelli, Paolo Maione, Antonio Rossi
The Oncologist|February 29, 2008
The potential role of mTOR inhibitors in non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
Pageof 36